Tatjana Mitchell compensation by year
Evolus Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $154,224 |
| Bonus | $100,000 |
| Stock awards | $1,420,509 |
| Option awards | $1,368,036 |
| Non-equity incentive | $111,200 |
| Pension and deferred compensation | $0 |
| All other | $9,303 |
| Total | $3,163,272 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Evolus, Inc. DEF 14A filed April 29, 2026, accession 0001570562-26-000059, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Evolus, Inc. filed document, accession 0001570562-26-000059. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 104,603 | $695,610 | — |
Per the Outstanding Equity Awards at Fiscal Year-End table in Evolus, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments Evolus discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Change in control and involuntary termination | $735,000 | $695,610 | $50,843 | $1,986,453 |
| Death | $0 | $695,610 | $0 | $695,610 |
| Involuntary termination without cause | $490,000 | $0 | $33,895 | $650,064 |
Per the Potential Payments Upon Termination or Change in Control table in Evolus, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
Evolus’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| David Moatazedi | President and Chief Executive Officer | $6,412,214 |
| Tatjana Mitchell · this page | Chief Financial Officer | $3,163,272 |
| Sandra Beaver | Former Chief Financial Officer | $1,699,898 |
| Rui Avelar | Chief Medical Officer and Head of Research and Development | $1,699,084 |
| Tomoko Yamagishi-Dressler | Former Chief Marketing Officer | $1,588,108 |
Tatjana Mitchell's compensation dossier, Evolus
You have read Tatjana Mitchell's totals and holdings. The dossier adds each equity grant Evolus disclosed for Tatjana Mitchell and Evolus's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Evolus compensation record
free company briefThis page is one person within Evolus's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Evolus proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Evolus's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Evolus's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order EOLS
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.